Literature DB >> 22431771

Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.

Virginie Lutz1, Dan Lipsker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22431771     DOI： 10.1001/archdermatol.2011.2473

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  10 in total

1.  DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?

Authors:  Edward W Cowen; Raphaela Goldbach-Mansky
Journal:  Arch Dermatol       Date:  2012-03

Review 2.  Autoinflammation: From monogenic syndromes to common skin diseases.

Authors:  Tien V Nguyen; Edward W Cowen; Kieron S Leslie
Journal:  J Am Acad Dermatol       Date:  2013-02-28       Impact factor: 11.527

3.  Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis.

Authors:  John W Frew; Dedee F Murrell
Journal:  Skin Appendage Disord       Date:  2017-04-29

4.  Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).

Authors:  S Cro; V R Cornelius; A E Pink; R Wilson; A Pushpa-Rajah; P Patel; A Abdul-Wahab; S August; J Azad; G Becher; A Chapman; G Dunnil; A D Ferguson; A Fogo; S A Ghaffar; J R Ingram; S Kavakleiva; E Ladoyanni; J A Leman; A E Macbeth; A Makrygeoegou; R Parslew; A J Ryan; A Sharma; A R Shipman; C Sinclair; R Wachsmuth; R T Woolf; A Wright; H McAteer; J N W N Barker; A D Burden; C E M Griffiths; N J Reynolds; R B Warren; H J Lachmann; F Capon; C H Smith
Journal:  Br J Dermatol       Date:  2021-08-19       Impact factor: 11.113

Review 5.  Psoriasis: from Pathogenesis to Targeted Therapies.

Authors:  Curdin Conrad; Michel Gilliet
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

6.  A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.

Authors:  Victoria Cornelius; Rosemary Wilson; Suzie Cro; Jonathan Barker; David Burden; Christopher E M Griffiths; Helen Lachmann; Helen McAteer; Nick Reynolds; Andrew Pink; Richard B Warren; Francesca Capon; Catherine Smith
Journal:  Trials       Date:  2018-08-29       Impact factor: 2.279

Review 7.  Pustular Psoriasis: The Dawn of a New Era.

Authors:  Hervez Bachelez
Journal:  Acta Derm Venereol       Date:  2020-01-30       Impact factor: 3.875

Review 8.  The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.

Authors:  Silvia Federici; Alberto Martini; Marco Gattorno
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561

Review 9.  Update on psoriasis immunopathogenesis and targeted immunotherapy.

Authors:  Satveer K Mahil; Francesca Capon; Jonathan N Barker
Journal:  Semin Immunopathol       Date:  2015-11-16       Impact factor: 9.623

10.  Acrodermatitis continua of Hallopeau: clinical perspectives.

Authors:  Mary Patricia Smith; Karen Ly; Quinn Thibodeaux; Tina Bhutani; Wilson Liao; Kristen M Beck
Journal:  Psoriasis (Auckl)       Date:  2019-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.